Loading
Memory Loss (excluding Dementia) / Presymptomatic Disease / Mild Cognitive Impairment · Observational Study
ClinicalTrials.gov · September 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registry record for an ongoing decentralized, multi-omics observational cohort study examining digital phenotyping for early detection of Alzheimer's disease and Parkinson's disease. No results are reported in this registry entry. The study aims to develop standardized protocols and sensitive digital biomarkers for preclinical and prodromal stages of neurodegenerative disease, with primary outcome measures focused on data harmonization and diagnostic discrimination (ROC-AUC) at 60 months.
Observational. Presymptomatic Disease, Mild Cognitive Impairment, Memory Loss (Excluding Dementia), Cognitive Change, Dementia, Alzheimer Disease, Parkinson's Disease and Par…; age from 45 Years; accepts healthy volunteers. Intervention: Mild Behavioural Impairment (MBI); Mild cognitive impairment (MCI); Prodromal Parkinson's Disease; Symptomatic Parkinson's. n = 100,000. 4 sites: Greece, Spain.
This is a registry record for an ongoing decentralized, multi-omics observational cohort study examining digital phenotyping for early detection of Alzheimer's disease and Parkinson's disease. No results are reported in this registry entry. The study aims to develop standardized protocols and sensitive digital biomarkers for preclinical and prodromal stages of neurodegenerative disease, with primary outcome measures focused on data harmonization and diagnostic discrimination (ROC-AUC) at 60 months.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Once results are published, this cohort may provide evidence on the diagnostic and prognostic utility of digital phenotyping for early identification of individuals at risk of cognitive or motor decline. Current registry entry does not support clinical recommendations.
This is a registry record for an ongoing observational cohort study with no published results; enrollment and data collection are in progress with follow-up extending to 60 months.
As stated by the source record.
Quoted from the source exactly as published.
Once results are published, this cohort may provide evidence on the diagnostic and prognostic utility of digital phenotyping for early identification of individuals at risk of cognitive or motor decline. Current registry entry does not support clinical recommendations.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT04701177). This is a study registration, not published results. Lead sponsor: Greece 2021 Committee. Recruitment status: ENROLLING_BY_INVITATION. Study type: OBSERVATIONAL. Enrollment: 100000 participants (ESTIMATED). Conditions: Presymptomatic Disease, Mild Cognitive Impairment, Memory Loss (Excluding Dementia), Cognitive Change, Dementia, Alzheimer Disease, Parkinson's Disease and Parkinsonism. Interventions: DIAGNOSTIC_TEST: Teleph0s digital phenotyping platform. Primary outcome measures: Establish standardized protocols for acquisition, transfer & analysis of clinical, digital, imaging, biologic and genetic data that can be used in the AD & PD research community. , baseline to 60 months; Comprehensive and uniformly acquired dataset , baseline to 60 months; Change in Diagnostic Area Under the Receiver Operating Characteristic Curve (ROC-AUC) , 60 months of follow up. Brief summary: The study is carried out as part of the GR2021 Priority project "Healthy Brains for life (Age 20-99): Digitally-enhanced personalized medicine study ANANEOS" and code numbered GR-00546 and it will look at the decentralized and remote assessment of the symptoms of preclinical stages in Alzheimer's disease and movement disorders, e.g. Parkinson's. For this study we are looking for participants aged over 45 without cognitive complaints or with subjective perception of cognitive decline or with mild cognitive complaints. Specific aims for the proposed study: a) to develop novel sensitive measures that can provide an early identification of those SCD and MCI individuals harboring AD pathology that are at high risk of cognitive worsening over time; b) to track pre-motor stages in Parkinson's disease and trials that enable active digital functional biomarkers; c) to track disease progression during pre-dementia and pre-motor stages in clinical practice and trials with measures that enable to capture subtle changes.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.